Neoadjuvant Hypofractionated Stereotactic Body Radiation Therapy Prior to Surgery for Hepatocellular Carcinoma: a Feasibility Study.

Hepatocellular carcinoma (HCC) is the fifth more common cancer in the world, with high mortality rates, due to the low number of patients who are eligible for therapy with curative intent, like surgical resection. Moreover, surgical resection is associated with a high risk of tumor recurrence, because of the tumor seeding through microscopic intrahepatic vessels that surround the tumor, the so-called "microvascular invasion". To adequately deal with this phenomenon, the surgeon has to perform either an 'anatomical' liver resection, which remove not only the tumor but also the whole correspond

Trial Details

NCT ID

NCT04587739

Phase

PHASE1

Sponsor

University Hospital, Lille

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

• Surgery with Neoadjuvant stereotactic body radiation therapy

Locations (sample)

• Lille, France|50.63391,3.05512

Key Eligibility Criteria

• Biopsy-proven hepatocellular carcinoma or EASL/AASLD criteria
• Single nodule, 3 to 8 cm of largest diameter
• Hepatocellular carcinoma eligible for conventional liver resection with curative intent (R0), without preoperative portal vein embolization

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →